摘要
目的:本研究评价冠心病合并左心功能不全患者在常规治疗情况下加用国产曲美他嗪的临床疗效及安全性。方法:64例冠心病合并左心功能不全(LVEF<35%)患者,平均年龄(61±9)岁,随即分为治疗组和对照组。治疗组在常规治疗的基础上加用国产曲美他嗪每日60mg,治疗12个月,随诊观察患者临床情况、左心室射血分数(LVEF)、左室舒张末期容积、心胸比率、动态心电图(Holter)记录的心肌缺血次数以及6min步行距离的变化。结果:治疗组患者心功能明显改善,LVEF由(31.6±7.5)%升至(40.7±9.8)%(P<0.01);左室舒张末期容积由(58.5±6.8)ml/m2减到(52.1±7.7)ml/m2(P<0.01);心胸比率由(57.2±5.6)%降至(53.0±6.9)%(P<0.01);Holter记录的心肌缺血次数由(3.6±4.8)次减至(1.2±3.4)次;6min步行距离由(134.8±47.1)m增至(340.9±56.5)m(P<0.01)。结论:国产曲美他嗪联合其他治疗心功能不全的药物,能够进一步改善冠心病合并左心功能不全患者的心功能,降低左室舒张末期容积,减少心肌缺血次数,增加6min步行距离。
Objective：To assess the effect and the safety of trimetazidine on the treatment of patients with coronary heart disease and left ventricular dysfunction. Methods：64 patients with coronary heart disease and left ventricular dysfunction were enrolled in this clinical trial and was divided into treatment group（n=33） and control group（n=31） . The treatment group received TMZ（20 mg,3 times per day） for 12 months addition to conventional therapy. Patients were followed up for 12 months and assessments included clinical evaluation,electrocardiography,echocardiography,Holter and 6 minutes walk distance. Results：All patients tolerated 60 mg of trimetazidine for 12 months,left ventricular ejection fraction（LVEF） was increased from（31.6±7.5） % to（40.7±9.8） %（P0.01） . Left ventricular end-diastolic volume（LVEDV） was decreased from（58.5±6.8） ml/m2 to（52.1±7.7） ml/m2（P〈0.01） . The cardio-thorax ratio was decreased from（57.2±5.6） % to（53.0±6.9） %（P〈 0.01） . Attacks of angina recorded by Holter was decreased from（3.6±4.8） to（1.2±3.4） （P〈0.01） . 6 minutes walk distance was increased from（134.8±47.1） m to（340.9±56.5） m（P〈0.01） . Conclusion：Trimetazidine seems to improve clinical status,ejection fraction and 6 minutes walk distance,and reduce angina onsets,LVEDV,without adverse effects in patients with ischemic cardiomyopathy.
出处
《中国当代医药》
2009年第25期5-6,共2页
China Modern Medicine
